Catherine Novack
Stock Analyst at JonesTrading
(4.65)
# 873
Out of 4,703 analysts
125
Total ratings
42.6%
Success rate
24.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Catherine Novack
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Rated: Hold | n/a | $0.721 | - | 7 | Jul 31, 2026 | |
| EQ Equillium | Rated: Hold | n/a | $2.21 | - | 5 | Jul 31, 2026 | |
| FEMY Femasys | Rated: Hold | n/a | $2.98 | - | 9 | Jul 31, 2026 | |
| CAPR Capricor Therapeutics | Downgraded: Hold | n/a | $9.40 | - | 10 | Jul 30, 2026 | |
| PRQR ProQR Therapeutics | Maintained: Buy | $11 → $10 | $2.07 | +383.09% | 4 | Jun 26, 2026 | |
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $135 | $57.93 | +133.04% | 1 | Jun 8, 2026 | |
| RZLT Rezolute | Reiterated: Buy | $6 | $4.58 | +31.00% | 8 | Jun 2, 2026 | |
| WVE Wave Life Sciences | Reiterated: Buy | $35 | $4.86 | +620.16% | 14 | May 19, 2026 | |
| IBIO iBio, Inc. | Maintained: Buy | $7 | $1.31 | +434.35% | 2 | May 13, 2026 | |
| KRRO Korro Bio | Upgraded: Buy | $23 | $12.24 | +87.91% | 3 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $7.47 | +301.61% | 2 | Apr 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.47 | - | 4 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $16.93 | - | 10 | Apr 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 → $13 | $3.83 | +239.43% | 9 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $143 → $209 | $157.24 | +32.92% | 7 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $43 | $36.75 | +17.01% | 1 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $33 | $5.38 | +513.38% | 1 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $9 | $1.48 | n/a | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $30 | $24.28 | n/a | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $2.17 | n/a | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 → $60 | $1.75 | n/a | 4 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $6.86 | n/a | 4 | Nov 15, 2021 |
Daré Bioscience
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $0.721
Upside: -
Equillium
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $2.21
Upside: -
Femasys
Jul 31, 2026
Rated: Hold
Price Target: n/a
Current: $2.98
Upside: -
Capricor Therapeutics
Jul 30, 2026
Downgraded: Hold
Price Target: n/a
Current: $9.40
Upside: -
ProQR Therapeutics
Jun 26, 2026
Maintained: Buy
Price Target: $11 → $10
Current: $2.07
Upside: +383.09%
Spruce Biosciences
Jun 8, 2026
Initiated Coverage: Buy
Price Target: $135
Current: $57.93
Upside: +133.04%
Rezolute
Jun 2, 2026
Reiterated: Buy
Price Target: $6
Current: $4.58
Upside: +31.00%
Wave Life Sciences
May 19, 2026
Reiterated: Buy
Price Target: $35
Current: $4.86
Upside: +620.16%
iBio, Inc.
May 13, 2026
Maintained: Buy
Price Target: $7
Current: $1.31
Upside: +434.35%
Korro Bio
May 8, 2026
Upgraded: Buy
Price Target: $23
Current: $12.24
Upside: +87.91%
Apr 16, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $7.47
Upside: +301.61%
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $0.47
Upside: -
Apr 10, 2026
Rated: Hold
Price Target: n/a
Current: $16.93
Upside: -
Feb 24, 2026
Maintained: Buy
Price Target: $7 → $13
Current: $3.83
Upside: +239.43%
Feb 24, 2026
Maintained: Buy
Price Target: $143 → $209
Current: $157.24
Upside: +32.92%
Dec 23, 2025
Initiated Coverage: Buy
Price Target: $43
Current: $36.75
Upside: +17.01%
Sep 30, 2025
Initiated Coverage: Buy
Price Target: $33
Current: $5.38
Upside: +513.38%
Aug 8, 2025
Maintained: Buy
Price Target: $6 → $9
Current: $1.48
Upside: n/a
Jun 25, 2025
Initiated Coverage: Buy
Price Target: $30
Current: $24.28
Upside: n/a
Nov 15, 2024
Reiterated: Buy
Price Target: $15
Current: $2.17
Upside: n/a
Jun 3, 2024
Maintained: Buy
Price Target: $160 → $60
Current: $1.75
Upside: n/a
Nov 15, 2021
Downgraded: Hold
Price Target: n/a
Current: $6.86
Upside: n/a